Oric Pharmaceuticals/$ORIC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Ticker
$ORIC
Sector
Primary listing
Employees
128
Headquarters
Website
ORIC Metrics
BasicAdvanced
$1.2B
-
-$1.89
1.69
-
Price and volume
Market cap
$1.2B
Beta
1.69
52-week high
$14.93
52-week low
$3.90
Average daily volume
1.4M
Financial strength
Current ratio
16.129
Quick ratio
15.652
Long term debt to equity
1.485
Total debt to equity
2.495
Profitability
EBITDA (TTM)
-148.484
Management effectiveness
Return on assets (TTM)
-27.69%
Return on equity (TTM)
-43.82%
Valuation
Price to book
3.38
Price to tangible book (TTM)
3.38
Price to free cash flow (TTM)
-7.595
Free cash flow yield (TTM)
-13.17%
Free cash flow per share (TTM)
-1.671
Growth
Earnings per share change (TTM)
7.82%
3-year earnings per share growth (CAGR)
-4.22%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Bulls say / Bears say
ORIC extended its projected cash runway into 2027 with $256 million in cash, cash equivalents, and investments as of December 31, 2024 under a refined operating plan, bolstering financial flexibility for late-stage programs (GlobeNewswire via Nasdaq)
The company entered into a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for first-line NSCLC patients harboring EGFR exon 20 insertion mutations, leveraging J&J’s bispecific antibody expertise to potentially enhance treatment efficacy (GlobeNewswire)
ORIC refined its registrational development plans for its lead candidates, prioritizing initiation of the first Phase 3 trial of ORIC-944 in mCRPC in H1 2026 and planned Phase 3 studies of ORIC-114 in 2026, demonstrating a clear strategic path to commercialization (RTTNews)
ORIC’s net loss widened to $30.0 million in Q1 2025 from $25.0 million a year earlier, reflecting escalating operating losses as the company advances its clinical programs (GlobeNewswire)
Research and development expenses climbed 12% year-over-year to $24.6 million and general and administrative costs rose 15% to $8.1 million in Q1 2025, increasing the company’s cash burn ahead of costly Phase 3 trials (GlobeNewswire)
ORIC raised $125 million in a May 2025 private placement at $6.50 per share, issuing approximately 19.2 million new shares, which poses dilution risk for existing shareholders if additional funding is required before commercialization (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oric Pharmaceuticals stock?
Oric Pharmaceuticals (ORIC) has a market cap of $1.2B as of November 04, 2025.
What is the P/E ratio for Oric Pharmaceuticals stock?
The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of November 04, 2025.
Does Oric Pharmaceuticals stock pay dividends?
No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Oric Pharmaceuticals dividend payment date?
Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.
What is the beta indicator for Oric Pharmaceuticals?
Oric Pharmaceuticals (ORIC) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.